Humanized VH4vκ1 CAR T cells exhibited efficient antitumor activity against B-cell lymphoma tumor in vivo. (A) Schema showing NOD/Scid IL2RᵞCnull (NSG) mice engrafted IV with enhanced GFP + firefly luciferase (ffluc) + Raji-WT cells followed by murine and humanized CAR T-cell treatments. Mock was used as the control group for FMC63 and humanized VH4vκ1- and 4D5-treated groups. (B-C) Tumor burden was determined using bioluminescent imaging (BLI; 11 technical replicates per group) and log-transformed flux is shown as linear mixed models for each treatment over time (day 21 and 28: P < .001 FMC63 vs 4D5; and P < .001 VH4vκ1 vs 4D5). (D) Survival of mice treated with murine FMC63 compared with the 2 humanized CARs was analyzed using a log-rank test, ∗∗P < .01. Representative data from n = 2 are presented.
